<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00409344</url>
  </required_header>
  <id_info>
    <org_study_id>2006-P-001827</org_study_id>
    <secondary_id>IND:74068</secondary_id>
    <nct_id>NCT00409344</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine for Postoperative Sedation in Patients Undergoing Repair of Thoracoabdominal Aortic Aneurysms</brief_title>
  <official_title>Phase 4 Study of Dexmedetomidine for Postoperative Sedation in Patients Undergoing Repair of Thoracoabdominal Aortic Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospira, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to test the hypothesis that time on the ventilator and
      ICU length of stay will be shorter in TAA patients given postoperative sedation with
      dexmedetomidine compared to those given standard sedation. Secondary endpoints are:
      requirement for sedatives vasoactive drugs incidence of postoperative delirium and cost
      analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Repair of thoraco-abdominal aortic aneurysms (TAA) is mostly performed in specialized
      centers. These centers report an operative mortality around 10%. In an analysis of 337
      consecutive TAA, Cambria et al reported pulmonary (44%), cardiac, (13.8 %) renal (13.5%) and
      postoperative spinal cord deficit as prominent complications. Due to the extent of the
      surgery and the high risk of complications, all these patients require post- operative care
      in the Intensive Care Unit (ICU). In 2003, the operation was performed in approximately 40
      patients at the Massachusetts General Hospital (MGH). The median length of stay in the ICU
      was 7 days (range 2-55) All patients required postoperative mechanical ventilation for
      greater than 48 h. During this period, a continuous intravenous infusion of propofol is
      normally used for sedation. Pain relief is provided by a continuous intravenous infusion of
      hydromorphone. This combination of sedation and analgesia is widely used at MGH and other
      institutions. Although very effective, it may cause respiratory depression and a deep
      sedative state, which may result in a prolonged requirement for mechanical ventilation.
      Lighter or more controllable sedation appears to be beneficial in this regard: daily wake up
      of intubated and sedated ICU patients decreases days on the ventilator and length of stay in
      the ICU.

      Dexmedetomidine is a highly specific Î±2 agonist with prominent central nervous system (CNS)
      and cardiovascular effects It is FDA-approved as a postoperative sedative-hypnotic agent for
      intensive care patients for use up to 24 hours. The drug has hypnotic, sedative, analgesic
      and anxiolytic actions, and it tends to cause a mild decrease in blood pressure and heart
      rate. Patients or healthy volunteers sedated with dexmedetomidine alone are easily arousable
      and have no apparent respiratory depression. Dexmedetomidine has synergistic hypnotic and
      analgesic interactions with virtually all CNS depressants tested. It significantly decreases
      sedative and opioid requirements during and after major surgical procedures.Other potentially
      beneficial effects that are not as well-documented include bronchodilation and the ability to
      induce a more 'physiologic' sleep than other hypnotics commonly used in the ICU.
      Dexmedetomidine sedation may also be associated with a lower incidence of delirium.

      Patients recovering from TAA surgery routinely require substantial ICU resources. If
      dexmedetomidine decreases the opioid and sedative requirement in these patients, it may
      potentially decrease the average number of days spent on the ventilator and in the ICU.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Surgical approach changed therefore subject enrollment not possible.
  </why_stopped>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to a Successful Spontaneous Breathing Trial.</measure>
    <time_frame>1/1/2008</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensive Care Unit Length of Stay</measure>
    <time_frame>1/1/2008</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoints Include:Amount of Sedative and Opiates Given</measure>
    <time_frame>1/1/2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Extubation</measure>
    <time_frame>1/1/2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Vasoactive Substances Used to Achieve Hemodynamic Stability</measure>
    <time_frame>1/1/2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmaco-economics</measure>
    <time_frame>1/1/2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Delirium; Number of Shifts During Which Delirium Was Diagnosed</measure>
    <time_frame>1/1/2008</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Sedation</condition>
  <condition>Respiration, Artificial</condition>
  <condition>Length of Stay</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexmedetomidine is a highly specific a2 agonist with prominent central nervous system and cardiovascular effects. A postoperative sedative-hypnotic agent for intensive care patients for use up to 24 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>A continuous infusion of dexmedetomidine will be started at a dose of 0.8mcg/kg/hr. This will continue for no longer than 24 hours. Four hours post extubation the study drug wii be discontinued using a standard tapering protocol: 0.6mcg/kg/hr for 4 hours then 0.4mcg/kg/hr for 4 hours, then 0.2 mcg/kg/hr for 4 hours and then 0.1mcg/kg/hr for 4 hours and then turned off.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>No other names have been specified</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Normal Saline will be given as the placebo and will administered at 0.8mcg/kg/hr</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>No other names have been specified</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All Patients over age 18 undergoing non-emergent repair of type I-III TAA

        Exclusion Criteria:

          -  Pregnancy

          -  Patients with hepatic impairment (increase of ALT or AST three times normal)

          -  Patient taking clonidine or tricyclic antidepressants.

          -  Patients taking opioids or benzodiazepines chronically (&gt; 2 doses a day for &gt; 1 month)

          -  Patients with second or third degree heart block without a pacer

          -  Patients undergoing emergency repair of TAA

          -  Intraoperative cardiac arrest

          -  Intraoperative massive blood loss (&gt;10 l)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Schmidt, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2006</study_first_submitted>
  <study_first_submitted_qc>December 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2006</study_first_posted>
  <results_first_submitted>February 26, 2009</results_first_submitted>
  <results_first_submitted_qc>August 7, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 16, 2009</results_first_posted>
  <last_update_submitted>September 16, 2009</last_update_submitted>
  <last_update_submitted_qc>September 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ulrich Schmidt, MD PhD</name_title>
    <organization>Massachusetts General Hospital</organization>
  </responsible_party>
  <keyword>Thoracoabdominal Aortic Aneurysm</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Mechanical ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period 10/10/2006 to 1/1/2008 from a surgical intensive care unit in a tertiary hospital.</recruitment_details>
      <pre_assignment_details>Unable to enroll participants due to hepatic impairment and many patients taking tricyclic antidepressants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Saline</title>
          <description>This group will recive saline</description>
        </group>
        <group group_id="P2">
          <title>Dexmedetomidine</title>
          <description>This group will receive dexmedetomidine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">No participants enrolled</participants>
                <participants group_id="P2" count="0">No participants enrolled</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">No participants were enrolled to completion</participants>
                <participants group_id="P2" count="0">No participants were enrolled to completion</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>no enrollment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Saline</title>
          <description>This group will recive saline</description>
        </group>
        <group group_id="B2">
          <title>Dexmedetomidine</title>
          <description>This group will receive dexmedetomidine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to a Successful Spontaneous Breathing Trial.</title>
        <description>Did not achieve this primary outcome due to no enrollment of participants. Unable to measure this outcome.</description>
        <time_frame>1/1/2008</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline</title>
            <description>This group will recive saline</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine</title>
            <description>This group will receive dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>Time to a Successful Spontaneous Breathing Trial.</title>
          <description>Did not achieve this primary outcome due to no enrollment of participants. Unable to measure this outcome.</description>
          <units>hours</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Endpoints Include:Amount of Sedative and Opiates Given</title>
        <description>Did not achieve this outcome due to no enrollment of participants</description>
        <time_frame>1/1/2008</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline</title>
            <description>This group will recive saline</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine</title>
            <description>This group will receive dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Endpoints Include:Amount of Sedative and Opiates Given</title>
          <description>Did not achieve this outcome due to no enrollment of participants</description>
          <units>milligram of sedative an opiate</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Extubation</title>
        <description>Did not achieve this outcome due to no enrollment of participants</description>
        <time_frame>1/1/2008</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline</title>
            <description>This group will recive saline</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine</title>
            <description>This group will receive dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Extubation</title>
          <description>Did not achieve this outcome due to no enrollment of participants</description>
          <units>hours</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Vasoactive Substances Used to Achieve Hemodynamic Stability</title>
        <description>Did not achieve this outcome due to no enrollment of participants, unable to measure this outcome</description>
        <time_frame>1/1/2008</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline</title>
            <description>This group will recive saline</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine</title>
            <description>This group will receive dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Vasoactive Substances Used to Achieve Hemodynamic Stability</title>
          <description>Did not achieve this outcome due to no enrollment of participants, unable to measure this outcome</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmaco-economics</title>
        <description>Did not achieve this outcome due to no enrollment of participants</description>
        <time_frame>1/1/2008</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline</title>
            <description>This group will recive saline</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine</title>
            <description>This group will receive dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmaco-economics</title>
          <description>Did not achieve this outcome due to no enrollment of participants</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Delirium; Number of Shifts During Which Delirium Was Diagnosed</title>
        <description>Did not achieve this outcome due to no enrollment of participants. Was unable to measure this outcome.</description>
        <time_frame>1/1/2008</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline</title>
            <description>This group will recive saline</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine</title>
            <description>This group will receive dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Delirium; Number of Shifts During Which Delirium Was Diagnosed</title>
          <description>Did not achieve this outcome due to no enrollment of participants. Was unable to measure this outcome.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intensive Care Unit Length of Stay</title>
        <description>The number of days each patient was in the Intensive Care Unit. Unable to measure this outcome due to no enrollment of participnats.</description>
        <time_frame>1/1/2008</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline</title>
            <description>This group will recive saline</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine</title>
            <description>This group will receive dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>Intensive Care Unit Length of Stay</title>
          <description>The number of days each patient was in the Intensive Care Unit. Unable to measure this outcome due to no enrollment of participnats.</description>
          <units>Days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Saline</title>
          <description>This group will recive saline</description>
        </group>
        <group group_id="E2">
          <title>Dexmedetomidine</title>
          <description>This group will receive dexmedetomidine</description>
        </group>
      </group_list>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Unable to enroll participants into the study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ulrich Schmidt, MD PhD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-6490</phone>
      <email>uschmidt@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

